EPIX Pharmaceuticals news from FierceBiotech
NewsSPOTLIGHT: Epix wins $7.5M milestone
Epix Pharmaceuticals says it's due a $7.5 million milestone payment from GSK now that it's launched a Phase IIb trial of a new therapy for Alzheimer's. Researchers say the therapy could one day be Read more...
Emerging Drug Developer: Epix Pharmaceuticals Epix follows a new course in developing CF program For most investors, the sweet spot in any biotech play is right around proof-of-concept data on a new therapy for a disease that afflicts a large Read more... Funds from non-profit groups flow to biotech R&D
Epix Pharmaceuticals said this morning that its development pact with the Cystic Fibrosis Foundation has mushroomed into a $50 million deal, adding $37.7 million to the $12 million already provided Read more...
Epix shares dive after mid-stage depression failure
Epix Pharmaceuticals has pulled the plug on its depression drug, saying that a mid-stage trial of PRX-00023 failed to demonstrate sufficient efficacy for major depression. Investors bailed on the Read more...
Epix shares soar on Alzheimer's trial data
Shares of Epix Pharmaceuticals soared 53 percent this morning on the news that its experimental Alzheimer's therapy proved efficacious, safe and well tolerated in a mid-stage trial. There was mixed Read more...
| Press ReleasesPRESS RELEASE: EPIX Pharmaceuticals Reports Compelling Clinical Results for PRX-03140 in Alzheimer's Disease EPIX Pharmaceuticals Reports Compelling Clinical Results for PRX-03140 in Alzheimer's Disease; Statistically Significant Improvement in Cognitive Function Achieved Within Two Weeks EPIX to Host Read more... |
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight